Brought to you by the HIV Prevention Justice Alliance.
WEDNESDAY, FEBRUARY 16, 2011
3:30-5:30 pm Eastern / 2:30-4:30 pm Central / 1:30-3:30 pm Mountain / 12:30-2:30 pm Pacific
For the first time, a multi-country trial has shown that the use of the oral anti-HIV drug Truvada, by HIV negative gay men, MSM and transgender women, decreased rates of HIV transmission. And CDC has now released an interim guidance on the use of PrEP in gay men and other men who have sex with men....
But these results and guides beg many questions about ethics, equity, access and human rights. Join us with trial investigators, community advocates, human rights activists and others for an informative and stimulating conversation.
Speakers have been asked to discuss:
What are the human rights and HIV prevention justice implications, possibilities, challenges of PrEP?
What are the questions of access and ethics around new prevention technology, and the level of community input and transparancy in decision-making processes
Vulnerable and Marginal populations – thoughts on access and equity
Can interest in new prevention tech can bring new players in the fight for new resources? How can we leverage different strengths to FULLY fund the fight against AIDS?
Find out who the speakers are, and register.
[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]
No comments:
Post a Comment